Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Zolpidem
Tablets, 10 mg, to Ambien® Tablets, 10 mg (Sanofi-Synthelabo Inc.) under fasting conditions
using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.